Communiqués Immunovia AB London S.E.

Actions

0G8X

SE0006091997

Equipement et technologie médicale avancés

Temps Différé London S.E. Autres places de cotation 16:45:34 03/11/2025			Varia. 5j.	Varia. 1 janv.
31,92 ^SEK	-32,03%		+17 400,00%	+13 658,62%

15/06	Immunovia présente de nouvelles données avant sa demande de remboursement auprès de Medicare	FW
15/06	Immunovia dévoile de nouvelles données de performance pour PancreaSure avant sa demande de prise en charge par Medicare	CI

Communiqués

15/06	Immunovia announces new performance data for PancreaSure ahead of upcoming application for Medicare coverage	AQ
10/06	Immunovia publishes final AFFIRM study results in Journal of Clinical Oncology confirming strong diagnostic performance of PancreaSure	AQ
13/05	BULLETIN FROM THE ANNUAL GENERAL MEETING ON 13 MAY 2026 IN IMMUNOVIA AB (PUBL)	AQ
11/05	Research update Immunovia, Q1 2026: Initial commercialisation phase on track	AQ
07/05	Immunovia Publishes Interim Report for January-March 2026	AQ
05/05	Immunovia launches ASSURE registry to evaluate real-world clinical impact of PancreaSure in high-risk pancreatic cancer surveillance	AQ
04/05	Immunovia : Proposal for resolution on (A) option program for board members; and (B) directed issue of warrants and approval of transfer of warrants (Proposal for resolution on A option program for board members and B directed issue of warrants and approval of transfer of warrants 45758458 v6)	PU
04/05	Immunovia invites to a presentation on the Q1 report and 2026 objectives	AQ
14/04	Immunovia : Proposal for resolution on (A) option program for management and key persons; and (B) directed issue of warrants and approval of transfer of warrants (Proposal for resolution on A option program for management and key persons and B directed issue of warrants and approval of transfer of warrants)	PU
14/04	Immunovia : Proposal for resolution on (A) option program for board members; and (B) directed issue of warrants and approval of transfer of warrants (Proposal for resolution on A option program for board members and B directed issue of warrants and approval of transfer of warrants )	PU
14/04	Immunovia : Proposal for resolution on authorization of the board to resolve on new issue of shares (Proposal for resolution on authorization regarding issues)	PU
14/04	Immunovia : Annual Report (Immunovia AB publ Annual Report 2025)	PU
14/04	Immunovia : Notice to annual general meeting 2026 (notice of annual general meeting in immunovia ab publ)	PU
14/04	Immunovia : Statement from nomination committee (Statement from nomination committee 2026)	PU
13/04	NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)	AQ
10/04	Immunovia publishes the Annual Report for 2025	AQ
10/04	Immunovia : Remuneration Report (Remuneration Report 2026 Updated)	PU
25/02	Research update Immunovia Q4 2025: Targeting Medicare sub-mission by mid-2026	AQ
24/02	Immunovia Publishes Full Year Report for 2025	AQ
23/02	Immunovia : Invitation to presentation of Immunovia's Q4 2025 report	PU
23/02	Invitation to presentation of Immunovia’s Q4 2025 report	AQ
23/01	Immunovia attends Aktiespararna Life Science	AQ
20/01	The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting	AQ
19/01	Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout	AQ
15/01	Immunovia establish the 2026 Nomination Committee	AQ